非酒精性脂肪性肝病患者粪便钙卫蛋白检测及其意义*

doi:10.3969/j.issn.1672-5069.2018.01.017

摘要/Abstract

摘要： 目的探讨粪便钙卫蛋白（FC）评估非酒精性脂肪性肝病（NAFLD）患者肠道炎症状态的应用价值。方法纳入NAFLD和健康人,采用酶联免疫吸附试验检测粪便钙卫蛋白水平,并收集两组研究对象的一般资料和血生化指标。结果 91例正常人和81例NAFLD患者体质指数（BMI）分别为（22.6±2.4） kg/m²和（28.5±4.0） kg/m²,腰围分别为（80.9±7.9） cm和（91.6±9.5） cm,血清谷草转氨酶（AST）分别为（19.3±4.8） u/L和（33.7±18.7） u/L,谷丙转氨酶（ALT）分别为（17.5±7.1） u/L和（55.0±44.5） u/L,甘油三酯（TG）分别为（0.9±0.3） mmol/L和（2.4±2.3） mmol/L,总胆固醇（TC）分别为（4.3±0.6） mmol/L和（5.1±1.3） mmol/L,差异均有统计学意义（P<0.05）;NAFLD组FC水平为43.0（18.8~87.0）μg/g,显著高于正常人的11.4（4.6~24.4）μg/g,差异有统计学意义（P<0.00）;NAFLD组和正常人FC水平大于50 μg/g者分别为48例（59.3%）和6例（6.6%）,两者构成比差异具有统计学意义（x²=55.178,P<0.001）;相关性分析显示,NAFLD患者FC水平与BMI、腰围、血清GGT、TC水平呈正相关（r=0.725,r=0.570,r=0.292,r=0.400,P值均<0.05）;多因素分析发现,低水平的HDL、高水平的TG、BMI和TC是NAFLD发病的独立危险因素（OR=0.011,OR=13.558,OR=1.821,OR=3.086,P值均<0.01）。结论 NAFLD患者粪便FC水平升高,反映肠道可能存在一定的炎症。

关键词: 非酒精性脂肪性肝病, 粪便钙卫蛋白, 肠道炎症

Abstract: Objective To assess the state of gut inflammation in patients with non-alcoholic fatty liver diseae （NAFLD） by using fecal calprotectin measurement. Methods In NAFLD patients and healthy persons,the fecal calprotectin levels were measured by enzyme-linked immunosorbent assay,and the demographic data and biochemical parameters were collected. Results Eighty-one NAFLD patients and 91 healthy subjects were recruited in this study. The body mass index（BMI） in the healthy controls and in the NAFLD patients were （22.6±2.4） kg/m² vs. （28.5±4.0） kg/m²,waist circumference were（80.9±7.9） cm vs. （91.6±9.5） cm,AST was （19.3±4.8） IU/L vs. （33.7±18.7） IU/L,ALT was （17.5±7.1） IU/L vs. （55.0±44.5） IU/L,TG was（0.9±0.3） mmol/L vs. （2.4±2.3） mmol/L,TC was（4.3±0.6） mmol/L vs. （5.1±1.3） mmol/L,all of the difference were statistically significant（P<0.05）;the fecal calprotectin levels in the patients with NAFLD was 43.0（18.8~87.0）μg/g,much higher than 11.4（4.6~24.4） μg/g in the control （P<0.001）;There were positive correlations between fecal calprotectin levels and BMI,waist circumference,TC and GGT（r=0.725,r=0.570,r=0.292,and r=0.400,respectively,all P<0.010）;Multivariate analysis demonstrated that a low level of HDL,and a high level of TG,BMI,and TC were independent risk factors for NAFLD（OR=0.011,OR=3.558,OR=1.821,OR=3.086,respectively,all P<0.01）. Conclusion Fecal calprotectin levles increases in NAFLD patients,which might reflect the inflammation state of the gut.

Key words: Nonalcoholic fatty liver disease, Fecal calprotectin, Gut inflammation

杨钊, 魏娟, 吴晓辰, 王少东, 汪芳裕, 杨妙芳. 非酒精性脂肪性肝病患者粪便钙卫蛋白检测及其意义^*[J]. 实用肝脏病杂志, 2018, 21(1): 72-75.

Yang Zhao, Wei Juan, Wu Xiaochen, et al. Fecal calprotectin measurement in patients with non-alcoholic fatty liver disease[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 72-75.

参考文献

[1] Younossi ZM,Koenig AB,Abdelatif D,et al. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence and outcomes. Hepatology,2016,64（1）:73-84.
[2] Loomba R,Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol,2013,10（11）:686-690.
[3] 曾民德. 非酒精性脂肪性肝病:回顾历史,展望未来. 实用肝脏病杂志,2016,19（2）:129-131.
[4] Volta U,Bonazzi C,Bianchi FB,et al. IgA antibodies to dietary antigens in liver cirrhosis. Ric Clin Lab,1987,17（3）:235-242.
[5] Tilg H,Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis. Hepatology,2010,52（5）:1836-1846.
[6] Henao-Mejia J,Elinav E,Jin C,et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature,2012,482（7384）:179-185.
[7] Steinbakk M,Naess-Andresen CF,Lingaas E,et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet,1990,336（8718）:763-765.
[8] Vermeire S,Van Assche G,Rutgeerts P. Laboratory markers in IBD:useful,magic,or unnecessary toys. Gut,2006,55（3）:426-431.
[9] D'incà R,Dal Pont E,Di Leo V,et al. Can calprotectin predict relapse risk in inflammatory bowel disease&quest. Am J Gastroenterol,2008,103（8）:2007-2014.
[10] Kolho KL,Korpela K,Jaakkola T,et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol,2015,110（6）:921-930.
[11] Montalto M,Gallo A,Santoro L,et al. Role of fecal calprotectin in gastrointestinal disorders. Eur Rev Med Pharmacol Sci,2013,17（12）:1569-1582.
[12] D'Haens G,Ferrante M,Vermeire S,et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis,2012,18（12）:2218-2224.
[13] Gundling F,Schmidtler F,Hapfelmeier A,et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. Liver Int,2011,31（9）:1406-1415.
[14] Alempijevic T,Stulic M,Popovic D,et al. The role of fecal calprotectin in assessment of hepatic encephalopathy in patients with liver cirrhosis. Acta Gastroenterol Belg,2014,77（3）:302-305.
[15] Marie I,Leroi AM,Menard JF,et al. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev,2015,14（6）:547-554.
[16] Pendyala S,Neff LM,Suárez-Farinas M,et al. Diet-induced weight loss reduces colorectal inflammation:implications for colorectal carcinogenesis. Am J Clin Nutr,2011,93（2）:234-242.
[17] Hardy T,Oakley F,Anstee QM,et al. Nonalcoholic fatty liver disease:Pathogenesis and disease spectrum. Annu Rev Pathol,2016,11（1）:451-496.
[18] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志,2007,10（1）：1-3.
[19] Coorevits L,Baert FJ,Vanpoucke HJ. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med,2013,51（4）: 825-831.
[20] Mehal WZ. The gut-liver axis:A busy two-way street. Hepatology,2012,55（6）:1647-1649.
[21] Miele L,Valenza V,La Torre G,et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology,2009,49（6）:1877-1887.
[22] Giorgio V,Miele L,Principessa L,et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease,and correlates with liver disease severity. Dig Liver Dis,2014,46（6）:556-560.
[23] Gabele E,Dostert K,Hofmann C,et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol,2011,55（6）: 1391-1399.
[24] Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology,2015,149（5）:1275-1285.
[25] Yamamoto T,Shiraki M,Bamba T,et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis,2014,29（4）:485-491.

非酒精性脂肪性肝病患者粪便钙卫蛋白检测及其意义^*

Fecal calprotectin measurement in patients with non-alcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[5]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[6]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[7]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[8]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[9]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[10]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[11]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[12]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[13]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[14]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.
[15]	钟燕, 苏淑婷综述, 宓余强审校. 非酒精性脂肪性肝病治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(1): 145-148.